Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Beam Therapeutics Inc. (BEAM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biotechnology issuer. Beam files reports and current reports with the U.S. Securities and Exchange Commission that describe its financial condition, clinical development progress and material corporate events related to its precision genetic medicines platform.
Investors can review Form 8-K filings in which Beam reports items such as quarterly financial results and significant transactions. For example, the company has used Form 8-K to furnish press releases announcing results for quarters ended June 30 and September 30, and to disclose an Agreement and Plan of Merger under which it acquired an early-stage life sciences company in exchange for upfront shares and potential milestone-based consideration.
In addition to 8-Ks, Beam’s periodic reports on Form 10-K and Form 10-Q (accessible via EDGAR and summarized on this page when available) typically include information on its base editing platform, programs such as risto-cel (formerly BEAM-101), BEAM-302 and BEAM-301, risk factors, liquidity and capital resources. These filings also describe regulatory designations, clinical trial status and collaboration arrangements that are important for understanding the company’s development-stage business.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify disclosures on topics like clinical milestones, cash runway, collaboration agreements and equity issuances. Real-time updates from EDGAR ensure that new Beam filings, including any future Forms 4 reporting insider transactions or proxy statements on executive compensation and governance, are surfaced promptly.
By combining official SEC documents with AI-generated overviews, this page helps investors and researchers analyze Beam’s regulatory history, financial reporting and material events that influence the BEAM stock narrative.
Beam Therapeutics Inc. reported in a current update that it estimates having approximately $1.25 billion in cash, cash equivalents and marketable securities as of December 31, 2025. This figure is preliminary, unaudited and may change as the company completes its year-end closing and prepares full financial statements, so the company cautions against placing undue reliance on the estimate.
Beam also highlighted progress across its base editing portfolio and described key anticipated milestones in a press release and updated corporate presentation furnished as exhibits. These materials will support upcoming conference appearances, including an investor presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Beam Therapeutics Inc. (BEAM) filed its Q3 2025 10‑Q, reporting continued investment in R&D and a larger net loss. License and collaboration revenue was $9.7 million for the quarter. Research and development expense reached $109.8 million and general and administrative expense was $26.7 million. Net loss was $112.7 million, or $1.10 per share.
Liquidity remains strong. Cash and cash equivalents were $267.96 million and marketable securities were $807.01 million, totaling $1.07 billion as of September 30, 2025. The company closed an underwritten public offering in March 2025 for net proceeds of $470.5 million and reported operating cash outflows of $261.8 million for the nine months.
Strategic updates: Beam acquired an early‑stage life sciences company on July 1, 2025 for total consideration of $14.5 million, including 403,128 shares valued at $6.7 million and contingent consideration initially valued at $7.7 million; in‑process R&D of $14.5 million was expensed. Beam noted an announced agreement on October 10, 2025 for Bristol Myers Squibb to acquire Orbital Therapeutics; Beam holds 75 million Orbital shares.
Beam Therapeutics furnished a Form 8-K to announce its financial results for the quarter ended September 30, 2025.
The company issued a press release, furnished as Exhibit 99.1. The information in Item 2.02 and Exhibit 99.1 is furnished and is not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated.
Beam Therapeutics (BEAM): A reporting person disclosed an open‑market sale of 459 shares of common stock on 10/27/2025 at $26.68 per share (transaction code S). Following the transaction, indirect beneficial ownership positions were reported as 1,139,443 shares via F‑Prime Capital Partners Healthcare Fund V LP, 14 shares via FMR Capital, Inc., and 841,231 shares held by persons and entities whose shares are subject to reporting by the undersigned.
FMR LLC and related parties reported a disposition of Beam Therapeutics (BEAM) common stock. On
Remarks clarify that Abigail P. Johnson is a director, chair and CEO of FMR LLC and that members of the Johnson family collectively control
Beam Therapeutics insider Bethany J. Cavanagh, who serves as SVP, Finance and Treasurer, reported a non‑discretionary sale of 467 shares of common stock on 10/01/2025 at a price of $24.53 per share. The filing shows 44,045 shares remained beneficially owned by the reporting person after the transaction. The form states the shares were sold automatically to cover tax withholding obligations arising from the vesting of restricted stock units granted on 9/30/2021 and 9/30/2024, and the sales were effected under a Rule 10b5‑1 trading plan adopted on 8/9/2024. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025.
Beam Therapeutics insider Christine Bellon, Chief Legal Officer, reported an automatic sale of 373 shares of common stock on 10/01/2025 at a price of $24.53 per share. The sale was made to satisfy tax withholding obligations triggered by the vesting of restricted stock units granted on 9/30/2021. The shares were sold under a Rule 10b5-1 trading plan adopted by the reporting person on 5/19/2023. After the transaction, the reporting person beneficially owned 116,921 shares.
John M. Evans, Beam Therapeutics Inc. CEO and director, reported option exercises and sales in early October 2025 under a Rule 10b5-1 plan. On 10/01/2025 and 10/02/2025 he exercised two stock option tranches at a $0.67 strike for 25,000 shares each and sold corresponding blocks of 25,000 shares on each date. The sales were executed as multiple transactions at weighted average prices of approximately $24.5062 (range $24.14–$24.92) and $24.6267 (range $24.22–$25.05). Following the reported acquisitions, Mr. Evans beneficially owned 1,011,667 shares directly and 103,000 shares indirectly via the John M. Evans, III 2018 Irrevocable Trust. The Form 4 notes the option grants dated 05/08/2018 with portions still exercisable and expiring on 05/08/2028, and that the trades were made pursuant to a trading plan adopted on 05/16/2025.
An insider filing under Rule 144 discloses the proposed sale of 25,000 common shares of Beam Therapeutics (BEAM). The shares were acquired via a stock option exercise and paid in cash on 10/02/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC with an indicated aggregate market value of $615,667.50 and the issuer's shares outstanding listed as 100,557,094. The filing also reports a prior sale of 25,000 shares on 10/01/2025 that generated $612,655.00 in gross proceeds. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Beam Therapeutics (BEAM) filed a Rule 144 notice disclosing a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $612,655.00. The filing reports 101,162,026 shares outstanding for the issuer.
The securities were acquired and paid for on 10/01/2025 by a stock option exercise from the issuer, with payment in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.